59-92-7

  • Product Name:2-amino-3-(3,4-dihydroxyphenyl)propanoicacid
  • Molecular Formula:C9H11NO4
  • Purity:99%
  • Molecular Weight:
Inquiry

Product Details;

CasNo: 59-92-7

Molecular Formula: C9H11NO4

Appearance: colorless crystalline powder

59-92-7 Name

Name

2-amino-3-(3,4-dihydroxyphenyl)propanoicacid

Synonym

2-amino-3-(3,4-dihydroxyphenyl)propanoicacid;3,4-Dihydroxyphenylalanine(form2);3,4-Dihydroxyphenyl-L-alanine;3,4-DIHYDROXY-L-PHENYLALANINE;3,4-L-DIHYDROXYPHENYLALANINE;3-(3,4-DIHYDROXYPHENYL)-L-ALANINE;3-HYDROXY-L-TYROSINE;BETA-(3,4-DIHYDROXYPHENYL)-L-ALANINE

 

59-92-7 Chemical & Physical Properties

Melting point 

276-278 °C(lit.)

Boiling point

448.4±45.0 °C at 760 mmHg

Density

1.5±0.1 g/cm3

Molecular Formula

C9H11NO4

Molecular Weight

197.188

Flash Point

225.0±28.7 °C

PSA

103.78000

LogP

-0.22

Exact Mass

197.068802

Vapour Pressure

0.0±1.1 mmHg at 25°C

Index of Refraction

1.655

Storage condition

2-8°C

 

59-92-7 Description

Levodopa is an amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS.

 

59-92-7 Uses

Levodopa is an immediate precursor of dopamine and product of tyrosine hydroxylase. It derived from vanillin is widely used for treatment of Parkinson’s disease, most often in combination with peripheral decarboxylase inhibitors such as benserazide and carbidopa.